CATALAYER NEWS
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer – Company Announcement - FT.com - Financial Times
Source: Financial Times · 2026-10-25
Full article text is available in the Catalayer news terminal.
MORE FROM FINANCIAL TIMES
Marco Rubio still owes Europe answers about America’s intentions - Financial Times
2026-10-25
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in Firs
2026-10-25
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancer
2026-10-25
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvaluma
2026-10-25
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death b
2026-10-25
RELATED ON CATALAYER
Mentioned Tickers
$ROG.SW · RocheRelated Topics
EV & Auto Industry NewsRELATED MARKETS
Prediction Markets